Top

Current Atherosclerosis Reports

Published in:

01-02-2018 | Coronary Heart Disease (S. Virani and S. Naderi, Section Editors)

Microvascular Coronary Dysfunction—an Overview

Author: Sahar Naderi

Published in: Current Atherosclerosis Reports | Issue 2/2018

Abstract

Purpose of Review

We will review the available data on the epidemiology, pathophysiology, diagnosis, and management of microvascular coronary dysfunction (MCD).

Recent Findings

The study of MCD was pioneered by the Women’s Ischemia Syndrome Evaluation (WISE) cohort. New techniques in the diagnosis of this condition, using invasive and noninvasive means, are helping to increase awareness of this condition as well as ways in which to treat it.

Summary

Microvascular coronary disease without epicardial involvement has become an increasingly recognized cause of cardiac chest pain, particularly in women. Dysfunction of the microvasculature related to endothelium-dependent and endothelial-independent factors likely results in symptoms and/or evidence of ischemia. Although there is a growing body of research, there is still much about MCD that we do not understand.

Kochanek KD, Murphy SL, Xu J, Tejada-Vera B. Deaths: final data for 2014. Natl Vital Stat Rep. 2016;65(4):1–122.PubMed

Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, et al. Heart disease and stroke statistics—2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113(6):e85–151. https://doi.org/10.1161/CIRCULATIONAHA.105.171600.CrossRefPubMed

Diver DJ, Bier JD, Ferreira PE, Sharaf BL, McCabe C, Thompson B, et al. Clinical and arteriographic characterization of patients with unstable angina without critical coronary arterial narrowing (from the TIMI-IIIA Trial). Am J Cardiol. 1994;74(6):531–7. https://doi.org/10.1016/0002-9149(94)90739-0.CrossRefPubMed

Sullivan AK, Holdright DR, Wright CA, Sparrow JL, Cunningham D, Fox KM. Chest pain in women: clinical, investigative, and prognostic features. BMJ. 1994;308(6933):883–6. https://doi.org/10.1136/bmj.308.6933.883.CrossRefPubMedPubMedCentral

Merz CN, Kelsey SF, Pepine CJ, Reichek N, Reis SE, Rogers WJ, et al. The Women’s Ischemia Syndrome Evaluation (WISE) study: protocol design, methodology and feasibility report. J Am Coll Cardiol. 1999;33(6):1453–61. https://doi.org/10.1016/S0735-1097(99)00082-0.CrossRefPubMed

Reis SE, Holubkov R, Conrad Smith AJ, Kelsey SF, Sharaf BL, Reichek N, et al. Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease: results from the NHLBI WISE study. Am Heart J. 2001;141(5):735–41. https://doi.org/10.1067/mhj.2001.114198.CrossRefPubMed

Marcus ML, Chilian WM, Kanatsuka H, Dellsperger KC, Eastham CL, Lamping KG. Understanding the coronary circulation through studies at the microvascular level. Circulation. 1990;82(1):1–7. https://doi.org/10.1161/01.CIR.82.1.1.CrossRefPubMed

Camici PG, d’Amati G, Rimoldi O. Coronary microvascular dysfunction: mechanisms and functional assessment. Nat Rev Cardiol. 2015;12(1):48–62. https://doi.org/10.1038/nrcardio.2014.160.CrossRefPubMed

Panza JA. Coronary atherosclerosis: extending to the microcirculation? Eur Heart J. 2010;31(8):905–7. https://doi.org/10.1093/eurheartj/ehq044.CrossRefPubMed

10.

Knaapen P, Camici PG, Marques KM, Nijveldt R, Bax JJ, Westerhof N, et al. Coronary microvascular resistance: methods for its quantification in humans. Basic Res Cardiol. 2009;104(5):485–98. https://doi.org/10.1007/s00395-009-0037-z.CrossRefPubMedPubMedCentral

11.

Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med. 2007;356(8):830–40. https://doi.org/10.1056/NEJMra061889.CrossRefPubMed

12.

Kuo L, Chilian WM, Davis MJ. Coronary arteriolar myogenic response is independent of endothelium. Circ Res. 1990;66(3):860–6. https://doi.org/10.1161/01.RES.66.3.860.CrossRefPubMed

13.

Sodha NR, Boodhwani M, Clements RT, Feng J, SH X, Sellke FW. Coronary microvascular dysfunction in the setting of chronic ischemia is independent of arginase activity. Microvasc Res. 2008;75(2):238–46. https://doi.org/10.1016/j.mvr.2007.06.008.CrossRefPubMed

14.

Liu Y, Gutterman DD. Vascular control in humans: focus on the coronary microcirculation. Basic Res Cardiol. 2009;104(3):211–27. https://doi.org/10.1007/s00395-009-0775-y.CrossRefPubMedPubMedCentral

15.

Kaufmann PA, Gnecchi-Ruscone T, Schafers KP, Luscher TF, Camici PG. Low density lipoprotein cholesterol and coronary microvascular dysfunction in hypercholesterolemia. J Am Coll Cardiol. 2000;36(1):103–9. https://doi.org/10.1016/S0735-1097(00)00697-5.CrossRefPubMed

16.

Naoumova RP, Kindler H, Leccisotti L, Mongillo M, Khan MT, Neuwirth C, et al. Pioglitazone improves myocardial blood flow and glucose utilization in nondiabetic patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 2007;50(21):2051–8. https://doi.org/10.1016/j.jacc.2007.07.070.CrossRefPubMed

17.

Camici PG, Olivotto I, Rimoldi OE. The coronary circulation and blood flow in left ventricular hypertrophy. J Mol Cell Cardiol. 2012;52(4):857–64. https://doi.org/10.1016/j.yjmcc.2011.08.028.CrossRefPubMed

18.

Recio-Mayoral A, Rimoldi OE, Camici PG, Kaski JC. Inflammation and microvascular dysfunction in cardiac syndrome X patients without conventional risk factors for coronary artery disease. JACC Cardiovasc Imaging. 2013;6(6):660–7. https://doi.org/10.1016/j.jcmg.2012.12.011.CrossRefPubMed

19.

Jones E, Eteiba W, Merz NB. Cardiac syndrome X and microvascular coronary dysfunction. Trends Cardiovasc Med. 2012;22(6):161–8. https://doi.org/10.1016/j.tcm.2012.07.014.CrossRefPubMedPubMedCentral

20.

Murthy VL, Naya M, Taqueti VR, Foster CR, Gaber M, Hainer J, et al. Effects of sex on coronary microvascular dysfunction and cardiac outcomes. Circulation. 2014;129(24):2518–27. https://doi.org/10.1161/CIRCULATIONAHA.113.008507.CrossRefPubMedPubMedCentral

21.

Crea F, Camici PG, Bairey Merz CN. Coronary microvascular dysfunction: an update. Eur Heart J. 2014;35(17):1101–11. https://doi.org/10.1093/eurheartj/eht513.CrossRefPubMed

22.

Shaw LJ, Merz CN, Pepine CJ, Reis SE, Bittner V, Kip KE, et al. The economic burden of angina in women with suspected ischemic heart disease: results from the National Institutes of Health–National Heart, Lung, and Blood Institute-sponsored Women’s Ischemia Syndrome Evaluation. Circulation. 2006;114(9):894–904. https://doi.org/10.1161/CIRCULATIONAHA.105.609990.CrossRefPubMed

23.

Diez-Delhoyo F, Gutierrez-Ibanes E, Loughlin G, Sanz-Ruiz R, Vazquez-Alvarez ME, Sarnago-Cebada F, et al. Coronary physiology assessment in the catheterization laboratory. World J Cardiol. 2015;7(9):525–38. https://doi.org/10.4330/wjc.v7.i9.525.CrossRefPubMedPubMedCentral

24.

Fearon WF, Balsam LB, Farouque HM, Caffarelli AD, Robbins RC, Fitzgerald PJ, et al. Novel index for invasively assessing the coronary microcirculation. Circulation. 2003;107(25):3129–32. https://doi.org/10.1161/01.CIR.0000080700.98607.D1.CrossRefPubMed

25.

Thomson LE, Wei J, Agarwal M, Haft-Baradaran A, Shufelt C, Mehta PK, et al. Cardiac magnetic resonance myocardial perfusion reserve index is reduced in women with coronary microvascular dysfunction. A National Heart, Lung, and Blood Institute-sponsored study from the Women’s Ischemia Syndrome Evaluation. Circ Cardiovasc Imaging. 2015;8(4):e002481. https://doi.org/10.1161/CIRCIMAGING.114.002481.CrossRefPubMed

26.

Naderi S, Cho LS. Cardiovascular disease in women: prevention, symptoms, diagnosis, pathogenesis. Cleve Clin J Med. 2013;80(9):577–87. https://doi.org/10.3949/ccjm.80a.13005.CrossRefPubMed

27.

Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol. 2003;23(2):168–75. https://doi.org/10.1161/01.ATV.0000051384.43104.FC.CrossRefPubMed

28.

Sun BJ, Hwang E, Jang JY, Kim DH, Song JM, Kang DH. Effect of rosuvastatin on coronary flow reserve in patients with systemic hypertension. Am J Cardiol. 2014;114(8):1234–7. https://doi.org/10.1016/j.amjcard.2014.07.046.CrossRefPubMed

29.

Zhou MS, Schulman IH, Raij L. Nitric oxide, angiotensin II, and hypertension. Semin Nephrol. 2004;24(4):366–78. https://doi.org/10.1016/j.semnephrol.2004.04.008.CrossRefPubMed

30.

Luscher TF, Yang Z. Calcium antagonists and ACE inhibitors. Effect on endothelium and vascular smooth muscle. Drugs. 1993;46(Suppl 2):121–32. https://doi.org/10.2165/00003495-199300462-00021.CrossRefPubMed

31.

Pauly DF, Johnson BD, Anderson RD, Handberg EM, Smith KM, Cooper-DeHoff RM, et al. In women with symptoms of cardiac ischemia, nonobstructive coronary arteries, and microvascular dysfunction, angiotensin-converting enzyme inhibition is associated with improved microvascular function: a double-blind randomized study from the National Heart, Lung and Blood Institute Women’s Ischemia Syndrome Evaluation (WISE). Am Heart J. 2011;162(4):678–84. https://doi.org/10.1016/j.ahj.2011.07.011.CrossRefPubMedPubMedCentral

32.

Cannon RO 3rd, Watson RM, Rosing DR, Epstein SE. Efficacy of calcium channel blocker therapy for angina pectoris resulting from small-vessel coronary artery disease and abnormal vasodilator reserve. Am J Cardiol. 1985;56(4):242–6. https://doi.org/10.1016/0002-9149(85)90842-2.CrossRefPubMed

33.

Lanza GA, Colonna G, Pasceri V, Maseri A. Atenolol versus amlodipine versus isosorbide-5-mononitrate on anginal symptoms in syndrome X. Am J Cardiol. 1999;84(7):854–6, A8. https://doi.org/10.1016/S0002-9149(99)00450-6.CrossRefPubMed

34.

Togni M, Vigorito F, Windecker S, Abrecht L, Wenaweser P, Cook S, et al. Does the beta-blocker nebivolol increase coronary flow reserve? Cardiovasc Drugs Ther. 2007;21(2):99–108. https://doi.org/10.1007/s10557-006-0494-7.CrossRefPubMed

35.

Mehta PK, Goykhman P, Thomson LE, Shufelt C, Wei J, Yang Y, et al. Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease. JACC Cardiovasc Imaging. 2011;4(5):514–22. https://doi.org/10.1016/j.jcmg.2011.03.007.CrossRefPubMed

36.

Jespersen L, Hvelplund A, Abildstrom SZ, Pedersen F, Galatius S, Madsen JK, et al. Stable angina pectoris with no obstructive coronary artery disease is associated with increased risks of major adverse cardiovascular events. Eur Heart J. 2012;33(6):734–44. https://doi.org/10.1093/eurheartj/ehr331.CrossRefPubMed

37.

Mygind ND, Michelsen MM, Pena A, Frestad D, Dose N, Aziz A, et al. Coronary microvascular function and cardiovascular risk factors in women with angina pectoris and no obstructive coronary artery disease: the iPOWER study. J Am Heart Assoc. 2016;5(3):e003064. https://doi.org/10.1161/JAHA.115.003064.CrossRefPubMedPubMedCentral

38.

Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000;101(9):948–54. https://doi.org/10.1161/01.CIR.101.9.948.CrossRefPubMed

39.

Pepine CJ, Anderson RD, Sharaf BL, Reis SE, Smith KM, Handberg EM, et al. Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia results from the National Heart, Lung and Blood Institute WISE (Women’s Ischemia Syndrome Evaluation) study. J Am Coll Cardiol. 2010;55(25):2825–32. https://doi.org/10.1016/j.jacc.2010.01.054.CrossRefPubMedPubMedCentral

Title: Microvascular Coronary Dysfunction—an Overview
Author: Sahar Naderi
Publication date: 01-02-2018
Publisher: Springer US
Published in: Current Atherosclerosis Reports / Issue 2/2018
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI: https://doi.org/10.1007/s11883-018-0710-5

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Microvascular Coronary Dysfunction—an Overview

Abstract

Purpose of Review

Recent Findings

Summary

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 2/2018

Nutrition and Cardiovascular Disease—an Update

Human Immunodeficiency Virus Infection, Antiretroviral Therapy, and Statin: a Clinical Update

Chemotherapeutic Agents and the Risk of Ischemia and Arterial Thrombosis

Diagnostic Error in Stroke—Reasons and Proposed Solutions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page